微信公众号

官网二维码

中国癌症防治杂志 ›› 2026, Vol. 18 ›› Issue (1): 87-97.doi: 10.3969/j.issn.1674-5671.2026.01.11

• 论著 • 上一篇    下一篇

FKBP10重塑细胞外基质在促进膀胱癌进展中的作用机制及临床意义#br#

  

  1. 广西医科大学第一附属医院泌尿外科;广西医科大学基因组与个体化医学研究中心;广西医科大学第一附属医院代谢与健康广西院士工作站;广西医科大学人文社会科学学院
  • 出版日期:2026-02-25 发布日期:2026-03-26
  • 通讯作者: 冯超 E?mail:fengchao@sr.gxmu.edu.cn; 李天宇 E?mail:litianyu@gxmu.edu.cn
  • 基金资助:
    广西自然科学基金项目(2024GXNSFBA010111);国家自然科学基金项目(82303316)

Mechanism and clinical implications of FKBP10 drives bladder cancer progression through the extracellular matrix remodeling

  • Online:2026-02-25 Published:2026-03-26

摘要: 目的 探讨FK506结合蛋白10(FK506⁃binding protein 10,FKBP10)在膀胱癌中的表达及其促进膀胱癌进展的作用机制与临床意义。方法 收集2018年1月至2023年2月在广西医科大学第一附属医院行全膀胱切除术的92例膀胱癌患者的肿瘤组织样本。根据患者FKBP10的转录组表达水平将其分为FKBP10高表达组和低表达组,评估两组患者的预后及临床特征。基于Bulk⁃RNA数据,通过差异基因分析、基因集富集分析和xCell算法分析FKBP10高表达组和低表达组患者的异质性特征;提取FKBP10高表达组中的差异上调基因,利用整合了ENCODE、ReMap等公共数据库ChIP⁃seq数据及RNA⁃seq共表达数据的ChEA3平台进行转录因子预测。单细胞测序数据应用CellChat算法分析FKBP10+细胞亚群与其他细胞间的相互作用。结果 FKBP10高表达组患者(n=23)的总生存期明显短于低表达组患者(n=69),且具有更高的T分期(均P<0.05)。FKBP10高表达组患者中细胞外基质(extracellular matrix,ECM)重塑、上皮⁃间充质转化和血管生成等肿瘤恶性进展相关通路显著激活,PRRX1和PRRX2为潜在的上游转录调控因子。免疫微环境相关分析显示,与FKBP10低表达患者相比,FKBP10高表达患者富集了M2型巨噬细胞且高表达免疫检查点分子。单细胞测序分析结果显示,FKBP10特异性高表达于癌症相关成纤维细胞(cancer⁃associated fibroblasts,CAFs)亚群。配体⁃受体分析显示,FKBP10+ CAFs可能通过分泌血管内皮生长因子B(vascular endothelial growth factor B,VEGFB)或胎盘生长因子(placental growth factor,PGF)配体,激活血管内皮生长因子受体1(vascular endothelial growth factor receptor 1,VEGFR1)促进血管生成。结论 FKBP10高表达的膀胱癌患者具有ECM重塑和高血管生成活性等特征,临床预后差。FKBP10的促癌机制可能与FKBP10+ CAFs通过重塑ECM,激活VEGFB/PGF⁃VEGFR1信号轴促进血管生成有关。 

关键词:  , 膀胱癌, FKBP10, 细胞外基质, 肿瘤微环境, 癌症相关成纤维细胞

Abstract: Objective Bladder cancer is a heterogeneous malignancy with highly metastasis and recurrence rates. Within the tumor microenvironment (TME), cancer⁃associated fibroblasts (CAFs) and extracellular matrix (ECM) remodeling critically influence tumor progression and therapeutic resistance. FK506⁃binding protein 10 (FKBP10) is a molecular chaperone involved in collagen folding and ECM homeostasis, has been implicated in various malignancies. However, its specific role and regulatory mechanisms within the bladder cancer TME remain insufficiently defined. This study aims to investigate the expression profile of FKBP10 in bladder cancer and to systematically elucidate its clinical significance and potential mechanisms in modulating the stromal niche to promote tumor malignancy. Methods Tumor tissue samples were collected from 92 bladder cancer patients who underwent radical cystectomy at The First Affiliated Hospital of Guangxi Medical University between January 2018 and February 2023. Patients were stratified into FKBP10 high⁃ and low⁃expression groups based on FKBP10 transcriptome levels to compare their prognosis and clinical characteristics. Based on Bulk RNA sequencing data, the intergroup heterogeneity were analyzed through differential gene analysis, Gene Set Enrichment Analysis (GSEA), and the xCell algorithm. Differentially upregulated genes in the FKBP10⁃high expression group were extracted and subjected to transcription factor prediction using ChEA3, which integrates ChIP⁃seq data from public repositories such as ENCODE and ReMap, along with RNA⁃seq co⁃expression datasets. Furthermore, the study applied the CellChat algorithm to decipher intercellular communication between FKBP10⁃positive cell subsets and other cell populations. Results In compared to the low⁃expression group (n=69), the high FKBP10 expression group (n=23) exhibited significantly shorter overall survival, along with higher T stage (all P<0.05). In patients with high FKBP10 expression, pathways associated with malignant tumor progression such as extracellular matrix (ECM) remodeling, epithelial⁃mesenchymal transition (EMT), and angiogenesis were significantly activated. PRRX1 and PRRX2 were identified as potential transcription factors regulating these processes. Analysis of the immune microenvironment revealed that the high⁃expression group indicated enrichment of M2 macrophages and elevated expression of immune checkpoint molecules. Single⁃cell RNA sequencing (scRNA⁃seq) analysis revealed that FKBP10 was predominantly expressed in CAFs. Ligand⁃receptor interaction analysis suggested that FKBP10+ CAFs may interact with endothelial cells through the VEGFB/PGF⁃VEGFR1 signaling axis. Conclusions FKBP10 acts as a driver of bladder cancer progression. High FKBP10 expression in bladder cancer is characterized by ECM remodeling and heightened angiogenic activity, which correlates with a poor clinical prognosis. The tumor⁃promoting mechanism likely involves FKBP10+ CAFs facilitating angiogenesis through ECM remodeling and activation of the VEGFB/PGF⁃VEGFR1 signaling axis.

Key words: Bladder cancer, FKBP10, Extracellular matrix, Tumor microenvironment, Cancer?associated fibroblasts

中图分类号: 

  • R737.14